Corona Remedies and Wakefit Innovations are set to list amid divergent grey market signals. Corona Remedies commands strong listing expectations backed by robust subscriptions and profitability, while Wakefit’s muted GMP reflects cautious sentiment towards consumer-facing growth businesses, highlighting current investor preference for earnings visibility and consistency.
Wockhardt shares rocket 19% after FDA approval for antibiotic targeting drug-resistant infections. Check details
Wockhardt’s shares surged 19% after the U.S. FDA approved ZAYNICH, a novel intravenous antibiotic for complicated urinary tract infections. The drug, combining cefepime and zidebactam,